The combineddata for all 3 trials showed a significantlyhigher rate of depression-freepatients in the Wellbutrin XL group:84.3% in the active group and 72.0% inthe placebo group. Patientswho did not tolerate the 300-mg dosecontinued the 150-mg dose. The dose wasinitiated at 150 mg daily for 1 week andthen increased to 300 mg daily. 2Ī total of 3 double-blind, placebo-controlledstudies evaluated the efficacy ofWellbutrin XL for the prevention of SAD inadults with a history of the disorder.Treatment began in the autumn and wasdiscontinued in the spring. WellbutrinXL does not inhibit monoamine oxidaseor the reuptake of serotonin. 2Īlthough the exact mechanism ofWellbutrin XL is unknown, it is believed toexert noradrenergic and/or dopaminergiceffects through weak inhibition of norepinephrineand dopamine uptake. 1,2 Its initial indicationwas for the treatment of majordepressive disorder. It is available as a convenientonce-daily tablet. Wellbutrin XL is the first medication tobe approved for the prevention of thesymptoms of SAD. An estimated 6% ofAmerican adults suffer from SAD. The disorder is believed tobe linked to seasonal changes of light.Symptoms often include depressedmood, overeating, weight gain, lethargy,and increased sleep. Alsoknown as major depressive disorder with a seasonal pattern, SAD is characterizedby depressive symptoms that begin in thefall or winter and subside in the springand summer. GlaxoSmithKline's Wellbutrin XL (bupropionhydrochloride (HCl) extendedreleasetablets) has received FDA approvalfor the prevention of seasonalaffective disorder (SAD) in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |